Talk Bio

Roche licenses Simcere’s trispecific T-cell engager in deal worth up to $1.53 billion

Roche’s Genentech signs ADC partnership with DualityBio worth over $1 billion

China’s biotech rise is becoming a U.S. national-security concern

Third patient death revealed in China's CAR-T and gene therapy trials, spotlighting IIT safety and transparency

Biogen's monoclonal antibody felzartamab wins first global approval in China

Chilling effect predicted as China biotech reaches R&D frontier

Garijo’s Plan to Revamp Sanofi: R&D Cleanup, More M&A, and a China Push Explained

AZ wins EU nod for camizestrant

AstraZeneca licenses EGFR lung cancer drug Zegfrovy from spinoff Dizal for up to $1.5B

Hengrui, Kailera’s GLP‑1 Pill Posts Encouraging Efficacy but High Side Effect Rates in Late‑Stage China Trials

US lawmakers intensify scrutiny of Chinese clinical trials, raising industry concerns over cost and disruption

AstraZeneca seals near $1.8B renal disease pact with CSPC

Recent US moves add hurdles to US investments in China biotech

Friday Five: FDA steps up to counter China’s clinical‑trial edge, AbbVie buys Apogee, and psychedelics hype yields real data

BIO board met with national security, health officials on China’s biotech rise, CEO says (June 2026 news digestable summary)

Ollin nets $330M to fund Phase 3 trials of Vabysmo challenger from China (OLN324)

Serapha Bio takes flight from Boundless merger with $230M and gene-editing prospect from China

As China biotech crackdown calls reverberate in Washington, the pushback gets louder, too Recent efforts in Washington to restrict U.S. investment and partnerships with Chinese biotech firms have triggered a fierce backlash from industry leaders and intensified concerns in Beijing, turning biotech into the latest front in the U.S.-China tech rivalry.

Akeso takes center stage at ASCO 2026 as China biotech cements its global arrival

Lilly bets $3B+ to add China's Haisco to growing list of partners in five‑program pact – June 2–3, 2026 update